Kloker Linus D, Yurttas Can, Lauer Ulrich M
Department of Clinical Tumor Biology, University Hospital, University of Tübingen, Tübingen, Germany,
Department of General, Visceral and Transplant Surgery, University Hospital, University of Tübingen, Tübingen, Germany.
Oncolytic Virother. 2018 Sep 5;7:79-93. doi: 10.2147/OV.S165479. eCollection 2018.
Oncolytic virotherapy constitutes an upcoming alternative treatment option for a broad spectrum of cancer entities. However, despite great research efforts, there is still only a single US Food and Drug Administration/European Medicines Agency-approved oncolytic virus available for clinical use. One reason for that is the gap between promising preclinical data and limited clinical success. Since oncolytic viruses are biological agents, they might require more realistic in vitro tumor models than common monolayer tumor cell cultures to provide meaningful predictive preclinical evaluation results. For more realistic invitro tumor models, three-dimensional tumor cell-culture systems can be employed in preclinical virotherapy research. This review provides an overview of spheroid and hydrogel tumor cell cultures, organotypic tumor-tissue slices, organotypic raft cultures, and tumor organoids utilized in the context of oncolytic virotherapy. Furthermore, we also discuss advantages, disadvantages, techniques, and difficulties of these three-dimensional tumor cell-culture systems when applied specifically in virotherapy research.
溶瘤病毒疗法是一系列癌症实体即将采用的替代治疗方案。然而,尽管进行了大量研究,但目前美国食品药品监督管理局/欧洲药品管理局批准用于临床的溶瘤病毒仍只有一种。原因之一是临床前数据前景良好与临床成功有限之间存在差距。由于溶瘤病毒是生物制剂,与普通单层肿瘤细胞培养相比,它们可能需要更现实的体外肿瘤模型,以提供有意义的临床前预测评估结果。为了建立更现实的体外肿瘤模型,三维肿瘤细胞培养系统可用于临床前病毒疗法研究。本文综述了溶瘤病毒疗法中使用的球体和水凝胶肿瘤细胞培养、器官型肿瘤组织切片、器官型筏培养和肿瘤类器官。此外,我们还讨论了这些三维肿瘤细胞培养系统在病毒疗法研究中的优势、劣势、技术和困难。